People with ER-positive, HER2-negative breast cancer are usually offered both chemotherapy and hormone (endocrine) treatment to reduce the risk of the cancer coming back in the breast or elsewhere. Currently we don’t have a single test that can tell us whether or not someone might benefit from chemotherapy, so some people may receive chemotherapy who don’t need it. Chemotherapy can have unpleasant short- and long-term side-effects.
The study is looking at whether the Prosigna test can predict if patients with breast cancer which has spread to lymph nodes or with larger cancers are likely to benefit from chemotherapy.
Who is it for?
OPTIMA may be right for you if you are a man or a woman, aged 40 years and over, and you have breast cancer that is hormone sensitive (oestrogen (ER) positive) and HER2 negative, and:
Study details
Following consent, all participants will provide a tumour sample from their surgery and will be randomised. The sample will be sent to Sydney, Australia for Prosigna testing.
If you join this clinical trial, you will be entered into one of two groups:
Group 1: usual treatment group; you will receive chemotherapy and hormone treatment.
Group 2 your treatment will depend on the result of the Prosigna test.
Or
The study aims to recruit 4500 participants from UK, Sweden, Norway, Australia and New Zealand. Waikato, Tauranga, Wellington and Palmerston North.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Subscribe for updates & stay in the loop with new studies.